Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for pancreatic cancer
|Recruiting||ART in LAP - Phase 1 open label trial of Abraxane (nab paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma||The Queen Elizabeth Hospital|
|Recruiting||ART IN LAP - Phase 1 open label trial of Abraxane (NAB-Pacitazel), administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma||Royal Adelaide Hospital|
|Recruiting||CL-SBP-101-01 A Phase 1a/1b Study of SBP-101 in Previously Treated Subjects with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.||Ashford Cancer Centre Research|
|Recruiting||HALO-109-301 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Pegylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with Hyaluronan High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma||Royal Adelaide Hospital|
|Recruiting||Halozyme Pancreatic A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan- High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma||Flinders Medical Centre|
|Not yet recruiting||NAPOLI 2 A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma||Flinders Medical Centre|
|Not Yet Recruiting||ZU545102 An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer||Royal Adelaide Hospital|